Bright Minds Biosciences Inc. DRUG
Bright Minds Biosciences Inc. (Nasdaq: DRUG) is a CNS/neurology/psychiatry drug developer. Its lead program, BMB-101, is in Phase 2 for drug-resistant epilepsies (absence epilepsy, developmental epileptic encephalopathy); Prader-Willi syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BMB-101 (5-HT2C Gq-biased agonist) BREAKTHROUGH study | absence epilepsy and DEE | small molecule | Phase 2 |
| BMB-101 exploratory study | Prader-Willi syndrome | small molecule | Phase 2 |
| BMB-105 (5-HT2C agonist) | Prader-Willi syndrome | small molecule | Pre-clinical |
| BMB-202 (5-HT2A agonist) | depression / neuropsychiatric | small molecule | Pre-clinical |
| BMB-201 (5-HT2A/2C agonist prodrug) | headache / pain | small molecule | Pre-clinical |
Recent results and decisions
- Nov 2, 2026clinical hold FDA places partial clinical hold on BMB-101 Phase 2 trial in DEE due to mouse toxicity and inadequate pediatric data.
The U.S. Food and Drug Administration has notified the Company via email that its investigational new drug application for Developmental and Epileptic Encephalopathies and related Protocol BMB-101-105 has been placed on a partial clinical hold following the FDA's review.
Filing - Jan 6, 2026positive Open-label Phase 2 absence cohort (n=11 evaluable) met primary endpoint with 73.1% median reduction in absence seizures >=3s, p=0.012.
73.1% median reduction in the number of absence seizure ≥3s. p = 0.012 (Wilcoxon Signed Rank Test)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.